DOP34: Deciphering immune-epithelial interactions in health and in Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Jowett, G.M.(1);Read, E.(1);Pena-Cearra, A.(1);Coman, D.(1); Coales, I.(1);Kromann, E.(1);Ilangovan, J.(1);Roberts, L.(2);Gentleman, E.(3);Lord, G.M.(4);Neves, J.F.(1)*;
(1)King@E@s College London, Centre for Host-Microbiome Interactions, London, United Kingdom;(2)Manchester University, Faculty of Biology- Medicine and Health, Manchester, United Kingdom;(3)King@E@s College London, Craniofacial & Regenerative Biology, London, United Kingdom;(4)University of Manchester, Faculty of Biology- Medicine and Health, Manchester, United Kingdom;
DOP35: Spatial transcriptomics reveals cellular niches associated with histological inflammation in postoperative Crohn’s DiseaseECCO'24Year: 2024
Authors: Battat, R.(1,2)*;Sangiorgi, B.(3);Linggi, B.(3);Gui, S.(4,5);Torti, D.(3);Smith, M.I.(3);Mehandru, S.(6);Longman, R.(2);Lukin, D.J.(2);Scherl, E.J.(2);Qin, L.(7);Ma, C.(3,8,9);Teft, W.(3);Vande Casteele, N.(4,10);
(1)University of Montreal Hospital Center, Division of Gastroenterology and Hepatology, Montreal, Canada;(2)Weill Cornell Medicine, Jill Roberts Center for IBD- Division of Gastroenterology and Hepatology, New York, United States;(3)Alimentiv Inc., Medical R&D, London, Canada;(4)AcelaBio, Department of Pathology, San Diego, United States;(5)University of Washington, Department of Laboratory Medicine and Pathology, Seattle, United States;(6)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology- Department of Medicine, New York, United States;(7)Weill Cornell Medical College of Cornell University, Division of Anatomic Pathology- New York-Presbyterian Hospital- Department of Pathology and Laboratory Medicine, New York, United States;(8)University of Calgary, Division of Gastroenterology & Hepatology- Cumming School of Medicine, Calgary, Canada;(9)University of Calgary, Department of Community Health Sciences- Cumming School of Medicine, Calgary, Canada;(10)University of California San Diego, Department of Medicine, La Jolla, United States;
DOP37: Noninvasive assessment of gut function using transcriptional recording sentinel cellsECCO'24Year: 2024
Authors: Zimmermann, J.(1,2)*;Macpherson, A.(1,2);
(1)Inselspital- University Hospital, Department of Visceral Surgery and Medicine, Bern, Switzerland;(2)University of Bern, Department for BioMedical Research, Bern, Switzerland;
DOP38: A rare KRT17+ population emerges from the epithelium in the inflamed intestinal mucosa of patients with Ulcerative ColitisECCO'24Year: 2024
Authors: Dotti, I.(1,2)*;Melón-Ardanaz , E.(1,2);Sanzo, Á.(1,2);Gudiño, V.(1,2);Corraliza, A.M.(1,2);Teubel, I.(1,2);Esteller, M.(1,2);Ricart, E.(1,2);Salas, A.(1,2);
(1)Fundació de Recerca Clínic Barcelona-Institut d@E@Investigacions Biomèdiques August Pi i Sunyer FRCB-IDIBAPS, Inflammatory Bowel Disease Unit, Barcelona, Spain;(2)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Ciberehd, Madrid, Spain;
DOP39: Constructing butyrate-producing yeast as a cell-dependent treatment option for Inflammatory Bowel DiseaseECCO'24Year: 2024
Authors: Wu, J.(1)*;Kang, G.(1);Wang, L.(1);Gao, M.(1);Meng, S.(1);Cao, X.(2);Li, B.(1);Huang, H.(1);
(1)Tianjin University, Department of Biochemical Engineering, Tianjin, China;(2)Tianjin Medical University General Hospital, Department of Gastroenterology and Hepatology, Tianjin, China;
DOP40: Inflammatory Bowel Disease single cell atlas construction to enable cell type-specific target identificationECCO'24Year: 2024
Authors: De Baets, G.(1);D@E@Rozario, J.(2);Gehrman, U.(3);Mattsson, J.(3);Castiblanco, D.(2);Kaymak, I.(2);Moldoveanu, A.L.(2);Giorgio, C.(2);Prandi, F.(2);Jawale, C.(4);Honsa, P.(5);Ruppova, K.(5);Valny, M.(5);Macuchova, E.(5);Elizaveta Freinkman, E.(5);Sponarova, J.(5);Platt, A.(1);Ort, T.(4);Corridoni, D.(2)*;
(1)AstraZeneca- BioPharmaceuticals R&D- Research and Early Development, Early Respiratory and Immunology- Translational Science and Experimental Medicine, Cambridge, United Kingdom;(2)AstraZeneca- BioPharmaceuticals R&D- Research and Early Development, Early Respiratory and Immunology- Bioscience Immunology, Cambridge, United Kingdom;(3)AstraZeneca- BioPharmaceuticals R&D- Research and Early Development, Early Respiratory and Immunology- Translational Science and Experimental Medicine, Gothenburg, Sweden;(4)AstraZeneca- BioPharmaceuticals R&D- Research and Early Development, Early Respiratory and Immunology- Bioscience Immunology, Gaithersburg, United States;(5)Immunai Inc., Immunai, New York, United States;
DOP41: Mucosal single-cell profiling of Crohn@E@s-like disease of the pouch reveal unique pathogenesis and therapeutic targetsECCO'24Year: 2024
Authors: Cao, S.(1)*;Deepak, P.(2);Colonna, M.(3);
(1)Washington University in St. Louis, gastroenterology, St. Louis, United States;(2)Washington University, Gastroenterology, St. Louis, United States;(3)Washington University, Pathology and Immunology, St. Louis, United States;
DOP43: Histologic improvement, attenuation of inflammation and microbiome modulation by engineered high acetate producing Saccharomyces boulardii in DSS-induced colitisECCO'24Year: 2024
Authors: Deleu, S.(1)*;Trindade de Carvalho , B.(2);Jacobs, I.(3);Vazquez Castellanos, J.(4,5);Verstockt, S.(1);Verstockt, B.(6,7);Arnauts, K.(1);Deprez, L.(1);Vissers, E.(1);Lenfant, M.(1);De Hertogh , G.(8);Huys, G.(4,5);Thevelein, J.(2);Raes, J.(4,5);Vermeire, S.(6,7);
(1)KU Leuven, Department of Chronic Diseases and Metabolism CHROMETA, Leuven, Belgium;(2)Bio-Incubator BIO4, Novelyeast bv, Leuven, Belgium;(3)KU Leuven, Department of Microbiology- Immunology and Transplantation, Leuven, Belgium;(4)KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium;(5)VIB, Center for microbiology, Leuven, Belgium;(6)KU Leuven, Department of Chronic Diseases and Metabolism CHROMETA, Leuven, Belgium;(7)University Hospital Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(8)University Hospital Leuven, Laboratory of Morphology and Molecular Pathology, Leuven, Belgium;
DOP44: Melatonin Ameliorates Colitis In DSS-fed Mice Via The SIRT1 PathwayECCO'24Year: 2024
Authors: Lin, B.(1,2);Mao, Q.(1,2);Zhang, W.(1,2); Zhang, Y.(1,2);Cao, Q.(1,2);Xu, M.(1,2); Liu, J.(1,2)*;
(1)Sir Run Run Shaw Hospital- College of Medicine Zhejiang University, Gastroenterology, Hangzhou, China;(2)Sir Run Run Shaw Hospital- College of Medicine Zhejiang University, Inflammatory bowel disease center, Hangzhou, China;
DOP45: Blood-derived neutrophils give rise to differentially activated populations in the mucosa of active Inflammatory Bowel Disease patientsECCO'24Year: 2024
Authors: Veny, M.(1,2)*;Sanzo-Machuca, A.(1);Corraliza, A.M.(1,2);Strobbe, F.(1,2);Garrido-Trigo, A.(1,2);Gudiño, V.(1,2);Melón-Ardanaz, E.(1,2);Esteller, M.(1,2);Teubel, I.(1,2);Masamunt, M.C.(1,2);Ordás, I.(1,2);Prieto, C.(1,2);Giner, À.(1,2);Martin-Cardona, A.(2,3);Esteve, M.(2,3);Ricart, E.(1,2);Salas, A.(1,2);
(1)Institut d@E@Investigacions Biomèdiques August Pi i Sunyer- IDIBAPS, Inflammatory Bowel Disease Unit, Barcelona, Spain;(2)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Ciberehd, Madrid, Spain;(3)Hospital Universitari Mútua Terrassa- Universitat de Barcelona, Department of Gastroenterology, Terrassa, Spain;
DOP46: Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH studyECCO'24Year: 2024
Authors: Narula, N.(1)*;Peerani, F.(2);Hansen, T.(3);Bessissow, T.(4);Bressler, B.(5);Arun, A.(1);Schmit, M.(6);Castelli, J.A.(1);Marshall, J.K.(1);
(1)McMaster University, Gastroenterology, Hamilton, Canada;(2)University of Alberta, Gastroenterology, Edmonton, Canada;(3)University of Manitoba, Gastroenterology, Winnipeg, Canada;(4)Montreal General Hospital site/McGill University Health Center, Gastroenterology, Montreal, Canada;(5)St. Paul’s Hospital/University of British Colombia, Gastroenterology, Vancouver, Canada;(6)GI Research Institute, Gastroenterology, Vancouver, Canada;Canadian IBD Research Consortium
DOP47: Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatmentECCO'24Year: 2024
Authors: Panaccione, R.(1)*;Melmed, G.Y.(2);Khanna, R.(3);D’Haens, G.(4);Danese, S.(5);Ford, S.(6);Anyanwu, S.I.(6);Garrison, A.(6);Lacerda, A.P.(6);Vermeire, S.(7);
(1)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(2)Cedars-Sinai Medical Center, F. Widjaja Inflammatory Bowel Disease Institute, Los Angeles, United States;(3)University of Western Ontario, Department of Medicine- Robarts Clinical Trials, London, Canada;(4)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(5)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(6)AbbVie, Inc., North Chicago, United States;(7)University Hospital Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;
DOP48: Faecal microbiota transplantation in active Ulcerative Colitis: Key lessons from a randomized controlled trial halted for futilityECCO'24Year: 2024
Authors: Deleu, S.(1)*;Caenepeel, C.(2,3);Vazquez Castellanos, J.F.(4,5);Arnauts, K.(1);Braekeleire, S.(1);Machiels, K.(1);Baert, F.(6);Mana, F.(7);Pouillon, L.(8);Hindryckx, P.(9);Lobaton Ortega , T.(9);Louis, E.(10);Franchimont, D.(11);Verstockt, B.(3,12);Ferrante, M.(1,3);Sabino, J.(3,12);Vieira-Silva, S.(4,13);Falony, G.(4,14);Raes, J.(4,5);Vermeire, S.(1,3);
(1)KU Leuven, Department of Chronic Diseases and Metabolism CHROMETA, Leuven, Belgium;(2)KU Leuven, Department of Chronic Diseases and MetabolismCHROMETA, Leuven, Belgium;(3)University Hospital Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium;(5)VIB, Center for Microbiology, Leuven, Belgium;(6)AZ Delta, Department of Gastroenterology and Hepatology, Roeselare, Belgium;(7)University Hospitals Brussel, Department of Gastroenterology and Hepatology, Brussels, Belgium;(8)Imelda Hospital, Department of Gastroenterology and Hepatology, Bonheiden, Belgium;(9)University Hospital Ghent, Department of Gastroenterology and Hepatology, Ghent, Belgium;(10)CHU Liège, Department of Gastroenterology and Hepatology, Liège, Belgium;(11)Erasmus Hospital Brussel, Department of Gastroenterology and Hepatology, Brussels, Belgium;(12)KU Leuven, Department of Chronic Diseases and Metabolism CHROMETA, Leuven, Belgium;(13)University Medical Center of the Johannes Gutenberg-University Mainz, Institute of Medical Microbiology and Hygiene and Research Center for Immunotherapy, Mainz, Germany;(14)University Medical Center of the Johannes Gutenberg-University Mainz, - Institute of Medical Microbiology and Hygiene and Research Center for Immunotherapy, Mainz, Germany;
DOP49: Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction studyECCO'24Year: 2024
Authors: Panés, J.(1)*;Dignass, A.(2);Lichtenstein, G.(3);Huang, K.H.(4);Germinaro, M.(4);Houck, N.(4);Han, C.(4);Miao, Y.(4);Zhang, H.(4);Abu Farsakh, N.(5);Patel, B.(6);Owczarek, D.(7);Hisamatsu, T.(8);Sands, B.(9);Bressler, B.(10);
(1)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(2)Department of Medicine I- Agaplesion Markus Hospital- Goethe University, Gastroenterology, Frankfurt, Germany;(3)University of Pennsylvania, Gastroenterology, Philadelphia, United States;(4)Janssen Research & Development- LLC, Gastroenterology, Spring House, United States;(5)King Abdullah University Hospital, Gastroenterology, Irbid, Jordan;(6)Peak Gastroenterology Associates PGA, Gastroenterology, Colorado Springs, United States;(7)Centrum Medyczne PROMED, Gastroenterology, Kraków, Poland;(8)Kyorin University, Gastroenterology, Tokyo, Japan;(9)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(10)University of British Columbia, Gastroenterology, Vancouver, Canada;QUASAR Clinical Investigators
DOP50: PINPOINT: The epidemiology of paediatric-onset Inflammatory Bowel Disease in the United Kingdom – a prospective, national, cohort study.ECCO'24Year: 2024
Authors: Henderson, P.(1)*;Dobson, L.(2);
(1)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom;(2)IBD Registry, Senior Management, London, United Kingdom;PINPOINT Collaborators and the IBD Registry
DOP51: Risk of kidney failure in patients with Inflammatory Bowel Disease undergoing colectomy: a nationwide cohort studyECCO'24Year: 2024
Authors: Yang, Y.(1)*;Ludvigsson, J.F.(1,2,3);Forss, A.(1,4);Faucon, A.L.(1,5);Faye, A.S.(6);Olen, O.(7,8,9);Sjölander, A.(1);Carrero, J.J.(1,10);
(1)Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden;(2)Örebro University Hospital, Department of Paediatrics, Örebro, Sweden;(3)Columbia University College of Physicians and Surgeons, Celiac Disease Center- Department of Medicine, New York- NY, United States;(4)Karolinska University Hospital, Gastroenterology Unit- Department of Gastroenterology- Dermatovenereology and Rheumatology, Stockholm, Sweden;(5)Paris-Saclay University, Department of Clinical Epidemiology- Centre for Epidemiology and Population Health, Villejuif, France;(6)New York University Grossman School of Medicine, Department of Medicine and Population Health, New York- NY, United States;(7)Karolinska Institutet, Clinical Epidemiology Division- Department of Medicine Solna, Stockholm, Sweden;(8)Stockholm South General Hospital, Sachs@E@ Children and Youth Hospital, Stockholm, Sweden;(9)Karolinska Institutet, Department of Clinical Science and Education- Södersjukhuset, Stockholm, Sweden;(10)Karolinska Institutet, Division of Nephrology- Department of Clinical Sciences- Danderyd Hospital, Stockholm, Sweden;
DOP52: Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12ECCO'24Year: 2024
Authors: Dignass, A.(1)*;Panés, J.(2);Rubin, D.T.(3);Huang, K.H.G.(4);Germinaro, M.(4);Pandya, D.(4);Han, C.(5);Miao, Y.(6);Zhang, H.(6);Gu, F.(7);Rowbotham, D.(8);Mihaly, E.(9);Bressler, B.(10);Lichtenstein, G.R.(11);Allegretti, J.R.(12);
(1)Agaplesion Markus Hospital, Medicine, Frankfurt, Germany;(2)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Inflammatory Bowel Disease Unit, Barcelona, Spain;(3)University of Chicago Medicine Inflammatory Bowel Disease Center-, Gastroenterology- Hepatology & Nutrition, Chicago, United States;(4)Janssen Research & Development- LLC, Clinical Research GI, Spring House, United States;(5)Janssen Global Services- LLC, Strategic Market Access, Malvern, United States;(6)Janssen Research & Development- LLC, Biostatistics, Spring House, United States;(7)Peking University Third Hospital, Gastroenterology, Beijing, China;(8)Auckland City Hospital, Gastroenterology and Hepatology, Auckland, New Zealand;(9)Semmelweis University, Internal Medicine, Budapest, Hungary;(10)University of British Columbia, Gastroenterology, Vancouver, Canada;(11)University of Pennsylvania, Medicine, Philadelphia, United States;(12)Brigham and Women’s Hospital Crohn’s and Colitis Center, Gastroenterology- Hepatology- and Endoscopy, Boston, United States;QUASAR Clinical Investigators
DOP53: Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn@E@s Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term ExtensionECCO'24Year: 2024
Authors: Ferrante, M.(1)*;Panaccione, R.(2);Colombel, J.F.(3);Dubinsky, M.(4);Hisamatsu, T.(5);Lindsay, J.O.(6);Song, A.(7);Neimark, E.(7);Zhang, Y.(8);Kligys, K.(9);Crowley, J.(9);Duan, W.R.(10);D’Haens, G.(11);
(1)KU Leuven, Department of Gastroenterology and Hepatology- University Hospitals Leuven, Leuven, Belgium;(2)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(3)Icahn School of Medicine at Mount Sinai, Henry D. Janowitz Division of Gastroenterology- Department of Medicine-, New York, United States;(4)Icahn School of Medicine at Mount Sinai, Susan and Leonard Feinstein IBD Center, New York, United States;(5)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(6)Queen Mary University of London, Centre for Immunobiology- Barts and The London School of Medicine and Dentistry, London, United Kingdom;(7)AbbVie, Clinical Development, North Chicago, United States;(8)AbbVie, Statistics, North Chicago, United States;(9)AbbVie, Medical Affairs, North Chicago, United States;(10)AbbVie, Pharmacovigilance and Patient Safety, North Chicago, United States;(11)University of Amsterdam, Department of Gastroenterology and Hepatology- Amsterdam UMC, Amsterdam, United States;
DOP54: Guselkumab and golimumab combination induction therapy in Ulcerative Colitis results in early local tissue healing that is sustained through guselkumab maintenance therapyECCO'24Year: 2024
Authors: Richards , D.(1);Vetter , M.(1);Germinaro , M.(1);Verstockt , B.(2);Atreya , R.(3)*;Panes , J.(4);Sands , B.E.(5);Feagan , B.(6);McRae , B.(7);Cua , D.(1);Branigan , P.(1);Freeman , T.C.(1);
(1)Janssen Research & Development LLC, Research & Development, Spring House, United States;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University Hospital Erlangen- Friedrich-Alexander University Erlangen-Nuremberg, Department of Medicine I- Gastroenterology- Endocrinology and Pneumology, Erlangen, Germany;(4)Hospital Clínic de Barcelona, IDIBAPS- CIBERehd, Barcelona, Spain;(5)Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology, New York, United States;(6)Alimentev Inc.- Western University, Gastroenterology, London, Canada;(7)Janssen Research & Development LLC, Research & Development, Cambridge, United States;
DOP55: High diagnostic accuracy of 4-probe methylation biomarkers in paediatric Inflammatory Bowel Disease by epigenome-wide analysisECCO'24Year: 2024
Authors: Noble, A.(1)*;Adams, A.T.(1,2);Nayak, K.M.(3);Kalla, R.(4);Ventham, N.(5);Cheng, G.(6);Ashton, J.J.(6,7);Hansen, R.(8);Croft, N.(9);Wilson, D.C.(10,11);Ennis, S.(6);Zilbauer, M.(3);Uhlig, H.H.(1,2,12);Satsangi, J.(1);
(1)University of Oxford, Translational Gastroenterology Unit- Nuffield Department of Experimental Medicine, Oxford, United Kingdom;(2)University of Oxford, Biomedical Research Centre, Oxford, United Kingdom;(3)University of Cambridge, Department of Paediatrics, Cambridge, United Kingdom;(4)University of Edinburgh, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom;(5)University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom;(6)University of Southampton, Department of Human Genetics and Genomic Medicine, Southampton, United Kingdom;(7)University of Southampton, Department of Paediatric Gastroenterology, Southampton, United Kingdom;(8)University of Dundee, Child Health- Division of Molecular and Clinical Medicine, Dundee, United Kingdom;(9)Queen Mary University of London, Blizard Institute- Faculty of Medicine and Dentistry-, London, United Kingdom;(10)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom;(11)University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom;(12)University of Oxford, Department of Paediatrics, Oxford, United Kingdom;
